Cancer Advances, Inc. Announces Issuance of New U.S. Patent DURHAM, N.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal (GI) cancers, announced that the U.S....

Cancer Advances, Inc. Announces Poster Presentation at ASCO GI DURHAM, N.C., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Cancer Advances, Inc., a clinical stage biopharmaceutical company developing therapeutics for gastrointestinal cancers, will present a poster at the...

Cancer Advances, Inc. announces a new publication “Vaccine Against Gastrin, a Polyclonal Antibody Stimulator, Decreases Pancreatic Cancer Metastases” in the American Journal of Physiology—Gastrointestinal and Liver Physiology Immune competent female mice with pancreatic cancer treated with Polyclonal Antibody Stimulator (PAS) vaccine had significantly smaller tumors and fewer metastases than control mice. PAS vaccine...

Cancer Advances, Inc. announces new publication: “Gastrin Vaccine Improves Response to Immune Checkpoint Antibody in Murine Pancreatic Cancer by Altering the Tumor Microenvironment”, in the journal Cancer Immunology, Immunotherapy Inactivation of the growth peptide gastrin modulates the tumor microenvironment of pancreatic cancer rendering it more susceptible to immune checkpoint antibody therapy.Polyclonal Antibody Stimulator...